Information sur le laboratoire
Waqqas Afif (M.D./M.Sc.)
ChercheurUnité de recherche clinique
Département de médecine (McGill)
Profil de recherche
Mots-clés
Maladie inflammatoire chronique de l'intestin • maladie de Crohn • colite ulcéreuse • médicaments biologiques • contrôle des médicaments thérapeutiquesIntérêts de recherche
Ma recherche porte sur la sécurité et l'efficacité des médicaments biologiques dans le traitement de la maladie inflammatoire chronique de l'intestin. Je m'intéresse au contrôle des médicaments thérapeutiques afin d'optimiser le traitement des patients atteints de la maladie inflammatoire chronique de l'intestin prenant des médicaments biologiques.Membre de l'équipe
| Nom | Poste |
|---|
Dernières publications
- Sealey, D. C., Ho, K. F., Zhou, Z. C., Clark, M., Feagan, B. G., Panaccione, R., Steinhart, A. H., Bolshtyansky, E., Williamson, M. & Afif, W. (2025). Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data. Canadian journal of gastroenterology & hepatology, vol. 2025, p. 5713315.
- Targownik, L., Afif, W., Singh, S., Siffledeen, J., Ma, C., McHugh, K., Charbonneau, J. & Rioux, L.-C. (2025). Treatment patterns for advanced therapies in Canadians with moderate-to-severe inflammatory bowel disease: a retrospective cohort analysis. Journal of the Canadian Association of Gastroenterology, vol. 8, p. 21-30.
- Zhen, J., Simoneau, M., Sharma, P., Germain, P., Watier-Levesque, P., Othman, A., Marshall, J. K., Afif, W. & Narula, N. (2024). Acceptability, feasibility, and impact of the MyGut digital health platform in the monitoring and management of inflammatory bowel disease. Journal of the Canadian Association of Gastroenterology, vol. 7, p. 423-430.
- Di Fonzo, D. M. P., Alabdulkarim, B., Yanofsky, R., Abduallah, Y., Golovics, P., Lakatos, P. L., Bitton, A., Wild, G., Afif, W. & Bessissow, T. (2024). Association Between Serum Ustekinumab Concentrations and Endoscopic Disease Activity in Moderate-to-Severe Crohn's Disease Patients. Crohn's & colitis 360, vol. 6, p. otae071.
- Pedicelli, A. & Afif, W. (2024). In active ulcerative colitis, risankizumab induced and maintained remission. Annals of internal medicine, vol. 177, p. JC127.
- Bacsur, P., Resál, T., Sarlós, P., Iliás, Á., Dalma Sümegi, L., Kata, D., Dávid, A., Farkas, B., Ivány, E., Bálint, A., Bősze, Z., Fábián, A., Bor, R., Szepes, Z., Afif, W., Bessissow, T., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241290636.
- Birck, M. G., Lukusa, L., Choquette, D., Boire, G., Maksymowych, W. P., Singh, H., Afif, W. & Bernatsky, S. (2024). Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data. BMC rheumatology, vol. 8, p. 47.
- Seow, C. H., Marshall, J. K., Stewart, E., Pettengell, C., Ward, R. & Afif, W. (2024). The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study. Journal of the Canadian Association of Gastroenterology, vol. 7, p. 290-298.
- Jairath, V., Afif, W., Bressler, B., Pope, J. E., Selchen, D., Targownik, L. E. & Panaccione, R. (2024). Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies. Journal of the Canadian Association of Gastroenterology, vol. 7, p. 282-289.
- Bacsur, P., Wetwittayakhlang, P., Resál, T., Földi, E., Vasas, B., Farkas, B., Rutka, M., Bessissow, T., Afif, W., Bálint, A., Fábián, A., Bor, R., Szepes, Z., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Accuracy of the Pancolonic Modified Mayo Score in predicting the long-term outcomes of ulcerative colitis: a promising scoring system. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241239606.
Voir aussi
